KCTD1 and colon adenocarcinoma: In particular, by knocking down KCTD1 in the human colon adenocarcinoma cell line, SW480, using CRISPR/CAS9 technology, we re-assessed its ability to downregulate β-catenin, a central actor in the WNT/β-catenin signalling pathway.